FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

FDA Explains Why Zepzelca Will Not be Withdrawn

Responding to a petition seeking the removal of approval for Jazz Pharmaceuticals lung cancer drug Zepzelca, FDA explains why it doesnt agree with the...

Human Drugs

FDA Approves Biologic for Some Myelomas

FDA gives accelerated approval to Janssens teclistamab-cqyv for some adults with relapsed or refractory multiple myeloma.

latest-news-card-1
Human Drugs

FDA Airs Daprodustat Safety Concerns

FDA medical reviewers tell members of the Cardiovascular and Renal Drugs Advisory Committee there are safety concerns with GlaxoSmithKlines anemia dru...

latest-news-card-1
Federal Register

ANDA In Vitro Release Test Studies Guide

Federal Register notice: FDA makes available a draft guidance entitled In Vitro Release Test Studies for Topical Products Submitted in ANDAs.

latest-news-card-1
Human Drugs

CGMP Violations at Nephron SC

FDA warns West Columbia, SC-based Nephron SC about CGMP and other violations at its drug manufacturing facility.

latest-news-card-1
Human Drugs

Panel Reviewing Ipsen NDA Postponed

FDA says it is postponing a 10/31 Endocrinologic and Metabolic Drugs Advisory Committee meeting that was scheduled to review and vote on an Ipsen Biop...

latest-news-card-1
Human Drugs

CGMP, Other Violations at Advanced Cosmetic Lab

FDA warns Chatsworth, CA-based Advanced Cosmetic Research Laboratories about CGMP violations and marketing of misbranded unapproved new drugs.

latest-news-card-1
Human Drugs

Jubilant Generics FDA-483

FDA releases the form FDA-483 with six observations from an inspection at Indias Jubilant Generics.

latest-news-card-1
Medical Devices

NeuroOne Medical Brain Electrodes Get Clearance

FDA clears a NeuroOne Medical Technologies 510(k) to market its Evo sEEG Electrode technology for temporary (less than 30 days) use for the recording,...

latest-news-card-1
Human Drugs

Imjudo/Imfinzi Approved for Liver Cancer

FDA approves AstraZenecas Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) for treating adult patients with unresectable liver cancer.